[HTML][HTML] BRAF gene and melanoma: Back to the future

M Ottaviano, EF Giunta, M Tortora, M Curvietto… - International Journal of …, 2021 - mdpi.com
As widely acknowledged, 40–50% of all melanoma patients harbour an activating BRAF
mutation (mostly BRAF V600E). The identification of the RAS–RAF–MEK–ERK (MAP kinase) …

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy

AM Grimaldi, E Simeone, D Giannarelli, P Muto… - …, 2014 - Taylor & Francis
Cancer radiotherapy (RT) may induce what is referred to as the “abscopal effect,” a
regression of non-irradiated metastatic lesions distant from the primary tumor site directly …

Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm …

PA Ascierto, M Mandalą, PF Ferrucci… - Journal of Clinical …, 2023 - ingentaconnect.com
PURPOSE Limited prospective data are available on sequential immunotherapy and
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS SECOMBIT is …

[HTML][HTML] Epigenetic regulation in melanoma: facts and hopes

EF Giunta, G Arrichiello, M Curvietto, A Pappalardo… - Cells, 2021 - mdpi.com
Cutaneous melanoma is a lethal disease, even when diagnosed in advanced stages.
Although recent progress in biology and treatment has dramatically improved survival rates …

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced …

E Simeone, G Gentilcore, D Giannarelli… - Cancer immunology …, 2014 - Springer
Background Ipilimumab can induce durable disease control and long-term survival in
patients with metastatic melanoma. Identification of a biomarker that correlates with clinical …

[HTML][HTML] Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

V Montesarchio, R Parrella, C Iommelli… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background The inflammatory pathology observed in severe COVID-19 disease caused by
the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is …

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy

N Mozzillo, E Simeone, L Benedetto, M Curvietto… - …, 2015 - Taylor & Francis
Melanoma is responsible for most skin cancer-related deaths and is one of the most
common cancers diagnosed in young adults. In melanoma, tumors can become established …

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

E Simeone, AM Grimaldi, L Festino… - …, 2017 - Taylor & Francis
The optimal sequencing of targeted treatment and immunotherapy in the treatment of
advanced melanoma is a key question and prospective studies to address this are ongoing …

[HTML][HTML] Serious haematological toxicity during and after ipilimumab treatment: a case series

E Simeone, AM Grimaldi, A Esposito… - Journal of medical case …, 2014 - Springer
Introduction Immunotherapy with the anti-cytotoxic T-lymphocyte antigen-4 monoclonal
antibody ipilimumab has been shown to improve overall survival in previously treated and …

[HTML][HTML] Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists

M Ottaviano, M Curvietto, P Rescigno… - … for Immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the
health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) …